thiazidetype

Thiazide-type diuretics are a class of medications that promote diuresis by inhibiting the sodium-chloride cotransporter (NCC) in the distal convoluted tubule of the nephron. This reduces sodium and chloride reabsorption, increases water excretion, and, indirectly, lowers blood pressure. They also decrease urinary calcium excretion, which can be beneficial in reducing kidney stone risk and may modestly improve bone density.

Representative agents include hydrochlorothiazide, chlorthalidone, indapamide, and metolazone. Chlorthalidone and indapamide often have longer durations of action than hydrochlorothiazide, enabling once-daily dosing in many regimens.

Clinical uses: thiazide-type diuretics are commonly employed as first-line therapy for essential hypertension, either alone or in combination with other antihypertensives, and for edema associated with congestive heart failure, cirrhosis, or nephrotic syndrome. They may be used to prevent calcium-containing kidney stones and to treat some forms of osteoporosis via hypercalcemia reduction.

Safety and adverse effects: potential electrolyte disturbances include hypokalemia, hyponatremia, and dehydration; hyperuricemia can precipitate gout; mild glucose intolerance may occur, particularly in at-risk patients. Thiazide-type diuretics are generally avoided in advanced renal impairment and during pregnancy unless specifically advised. Interactions: NSAIDs can reduce diuretic efficacy; caution is needed when combined with agents affecting electrolyte balance or with lithium.

This overview summarizes the class commonly referred to as thiazide-type diuretics. Individual agents differ in potency, duration, and metabolic effects, guiding tailored therapy.